Advertisement

Topics

Achillion Company Profile

14:54 EDT 23rd September 2018 | BioPortfolio

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced multiple product candidates with novel mechanisms of action. Achillion is focused on solutions for the most challenging problems in infectious disease — HIV, hepatitis and resistant bacterial infections. Achillion’s drug development pipeline is led by elvucitabine (Beta-L-Fd4C or ACH-126,443), which is currently in late-stage Phase 2 clinical trials for the treatment of patients infected with HIV. Achillion’s candidate for the potential treatment of HCV infection, ACH-806, is in a Phase 1 clinical trial and is anticipated to be completed by the first half of 2006.

Location

300 George Street
New Haven,
Connecticut
06511
United States of America

Contact

Phone: 203-624-7000
Fax: 203-624-7003
Email: info@achillion.com


News Articles [48 Associated News Articles listed on BioPortfolio]

-$0.14 EPS Expected for Achillion Pharmaceuticals (ACHN) This Quarter

Brokerages expect Achillion Pharmaceuticals to announce earnings of per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have issued estimates for Achillion Pharm...

#news #biotech Chutes and Ladders—Achillion appoints Joseph Truitt CEO

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Chutes and Ladders—Achillion appoints Joseph Truitt CEO .Achillion appoints...

Achillion Pharmaceuticals (ACHN) Upgraded to "Buy" by Zacks Investment Research

The firm currently has $4.00 price objective on the biopharmaceutical company's stock. According to Zacks, "Achillion has no approved product in its portfolio and focuses on developing small molec...

Achillion Pharmaceuticals (ACHN) Downgraded by Zacks Investment Research

According to Zacks, "Achillion generated no revenue in Q3 while loss was narrower than the estimates. The company has no approved product in its portfolio and focuses on developing small molecule ther...

Achillion CEO Leaves As Biotech Enters Fight In New Drug Direction

NEW HAVEN: Achillion Pharmaceuticals [Nasdaq" ACHN] CEO Millind Deshpande is retiring and is being replaced by Joseph Truitt. Truitt had been named president and COO earlier in the year as the company...

Achillion Pharmaceuticals (ACHN) Stock Price Up 7.8%

Achillion Pharmaceuticals, Inc. shares rose 7.8% during trading on Thursday . The stock traded as high as $4.03 and last traded at $4.01.

#news #biotech Deshpande leaves Achillion after overseeing R&D pivot, leaving CEO chair free for Truitt

Biotechnology, Pharma and Biopharma News – Research – Science – Lifescience ://Biotech-Biopharma-Pharma: Deshpande leaves Achillion after overseeing R&D pivot, leaving CEO chair...

Somewhat Positive News Coverage Somewhat Unlikely to Affect Achillion ...

News stories about Achillion Pharmaceuticals have been trending somewhat positive recently, according to Accern Sentiment Analysis. The research group ranks the sentiment of press coverage by monitori...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [2 Associated Clinical Trials listed on BioPortfolio]

Safety and Antiviral Study of ACH-126, 443 (Beta-L-Fd4C) in the Treatment of Adults With Chronic Hepatitis B Infection.

The purpose of this study is to determine the safety and antiviral HBV activity of ACH-126,443 (beta-L-Fd4C) in the treatment of Subjects of Previous Achillion-Sponsored Phase 1 and 2 Stud...

Study of Once Daily Elvucitabine Versus Lamivudine in Subjects With a Documented M184V Mutation

HIV-1 infected patients receiving long-term therapy with lamivudine or emtricitabine (nucleoside reverse transcriptase inhibitors [NRTIs]) are at risk for the development of a mutation at ...

Companies [2 Associated Companies listed on BioPortfolio]

Achillion

Achillion is an innovative pharmaceutical company dedicated to bringing important new treatments to patients with infectious disease. The Company’s discovery and development teams have advanced mult...

Achillion Pharmaceuticals

Achillion is a privately held pharmaceutical company focused on the discovery, development and commercialization of innovative small molecule drugs that combat drug resistance in infectious diseases, ...

More Information about "Achillion" on BioPortfolio

We have published hundreds of Achillion news stories on BioPortfolio along with dozens of Achillion Clinical Trials and PubMed Articles about Achillion for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Achillion Companies in our database. You can also find out about relevant Achillion Drugs and Medications on this site too.

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Infectious-diseases
Antiretroviral Therapy Clostridium Difficile Ebola HIV & AIDS Infectious Diseases Influenza Malaria Measles Sepsis Swine Flu Tropical Medicine Tuberculosis Infectious diseases are caused by pathogenic...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...


Corporate Database Quicklinks



Searches Linking to this Company Record